Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2008-05-20
2008-05-20
Helms, Larry R. (Department: 1643)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C536S023100, C435S006120
Reexamination Certificate
active
10505377
ABSTRACT:
An isolated or purified nucleic acid molecule consisting essentially of a nucleotide sequence encoding a human or a non-human BORIS, or a fragment of either of the foregoing; an isolated or purified nucleic acid molecule consisting essentially of a nucleotide sequence that is complementary to a nucleotide sequence encoding a human or a non-human BORIS, or a fragment of either of the foregoing; a vector comprising such an isolated or purified nucleic acid molecule; a cell comprising such a vector; an isolated or purified polypeptide molecule consisting essentially of an amino acid sequence encoding a human or a non-human BORIS, or a fragment of either of the foregoing; a cell line that produces a monoclonal antibody that is specific for an aforementioned isolated or purified polypeptide molecule; and the monoclonal antibody produced by the cell line; methods of diagnosing a cancer or a predisposition to a cancer in a male or female mammal; a method of prognosticating a cancer in a mammal; a method of assessing the effectiveness of treatment of a cancer in a mammal; a method of treating a mammal prophylactically or therapeutically for a cancer, and a composition comprising a carrier and an inhibitor of BORIS.
REFERENCES:
patent: 5279721 (1994-01-01), Schmid
patent: 5801030 (1998-09-01), McVey et al.
patent: 5837511 (1998-11-01), Falck-Pedersen et al.
patent: 5849561 (1998-12-01), Falck-Pedersen
patent: 5972643 (1999-10-01), Lobanenkov et al.
patent: WO 97/12986 (1997-04-01), None
patent: WO 98/53087 (1998-11-01), None
patent: WO02074913 (2002-09-01), None
Skolnick, J. and Fetrow, J.S. From genes to protein structure and function: novel applications of computational approaches in the genomic era. 2000. Trends in Biotechnology. vol. 18 No. 1, pp. 34-39.
Burgess, Shaheen, Ravera, Jaye, Donahue, and Winkles Possible dissociation of the heparin-binding and mitogenic activities of heparin-binding (acidic fibroblast) growth factor-1 from its receptor-binding activites by site-directed mutagenesis of a single lysine residue. 1990. Journal of Cell Biology, vol. 111, pp. 2129-2138.
Lazar, E., Watanabe, S., Dalton, S., andd Sporn, M.B. Transforming growth factor a: mutation of aspartic acid 47 and leucine 48 results in different biological activities. 1988. Molecular and Cellular Biology, vol. 8 No. 3, pp. 1247-1252.
Schwartz, G.P., Burke, G.T., and Katsoyannis, P.G. A superactive insulin: [B10-aspartic acid] insulin (human). 1987. Proceedings of the National Academy of Sciences, vol. 84, pp. 6408-6411.
Lin, M.C., Wright, D.E., Hruby, V.J., and Rodbell, M. Structure-function relationships in glucagon: properties of highly purified Des-His1-, Monoiodo-, and [Des-Asn28, Thr29](homoserine lactone27)-glucagon. 1975. Biochemistry, vol. 14, pp. 1559-1563.
Freshney, R.I. Culture of Animal Cells, Alan R. Liss, Inc. 1983. New York. p. 4.
Dermer, G.B. Another anniversary for the war on cancer. 1994. Biotechnology, vol. 12, p. 320.
Galcheva-Gargova, Z., Konstantinov, K.N., Wu, I., Klier, F.G., Barrett, T., and Davis, R.J. Binding of zinc finger protein ZPR1 to the epidermal growth factor receptor. 1996. Science, vol. 272, pp. 1797-1802.
Klenova et al.,Seminars in Cancer Biology, 12, 399-414 (2002).
Loukinov et al.,PNAS, 99(10), 6806-6811, (May 14, 2002).
D'Arcy et al., “The Potential of BORIS Detected in the Leukocytes of Breast Cancer Patients as an Early Marker of Tumorigenesis,”Clin. Cancer Res., 12(20), pp. 5978-5986, (Oct. 15, 2006).
Risinger et al., “Global Expression Analysis of Cancer/Testis Genes in Uterine Cancers Reveals a High Incidence of BORIS Expression,”Clin. Cancer Res., 13 (6), pp. 1713-1719, (Mar. 15, 2007).
Adair et al.,Proc. Natl. Acad. Sci. USA, 86, 4574-4578 (Jun. 1989).
Arnold et al.,Gene, 253, 209-214 (2000).
Awad et al.,J. Biol. Chem., 274 (38), 27092-27098 (1999).
Bell et al.,Cell, 98, 387-396 (Aug. 6, 1999).
Bell et al.,Nature, 405, 482-485 (May 25, 2000).
Bird,Nature, 321, 209-213 (May 15, 1986).
Capecchi,Science, 244, 1288-1292 (Jun. 1989).
Chernukhin et al.,J. Biol. Chem., 275 (38), 29915-29921 (Sep. 22, 2000).
Feinberg,PNAS, 98 (2), 392-394 (Jan. 16, 2001).
Filippova et al.,Mol. Cell. Biol., 16 (6), 2802-2813 (Jun. 1996).
Filippova et al.,Nature Genetics, 28, 335-343 (Aug. 2001).
Filippova et al.,Cancer Research, 62 (1), 48-52 (2002).
GenBank accession # AF313621, Moore et al. (2002).
Hark et al.,Nature, 405, 486-489 (May 25, 2000).
Johnson et al.,Science, 245, 1234-1236 (Sep. 15, 1989).
Kanduri et al.,Current Biology, 10 (14), 853-856 (2000).
Klenova et al.,Mol. Cell Biol., 13 (12), 7612-7624 (Dec. 1993).
Klenova et al.,J. Biol. Chem., 273 (41), 26571-26579 (Oct. 9, 1998).
Klenova et al.,Mol. Cell. Biol., 21 (6), 2221-2234 (Mar. 2001).
Kostic et al.,Oncogene, 19, 3978-3987 (2000).
Lichtsteiner et al.,Cell, 51, 963-973 (Dec. 24, 1987).
Lobanenkov et al.,Oncogene, 5, 1743-1753 (1990).
Lutz et al.,Biochem. Soc. Trans., 28 (4), 386-390 (2000).
Lutz et al.,Nuc. Acids Res., 28 (8), 1707-1713 (2000).
Mansour et al.,Nature, 336, 348-352 (Nov. 1988).
Nakagawa et al.,PNAS, 98 (2), 591-596 (Jan. 16, 2001).
Ohlsson et al.,Trends in Genetics, 17 (9), 520-527 (Sep. 2001).
Pack et al.,Cancer Res., 59, 5560-5564 (Nov. 1, 1999).
Quitschke et al.,Nuc. Acids Res., 28 (17), 3370-3378 (2000).
Rasko et al.,Cancer Res., 61, 6002-6007 (Aug. 15, 2001).
Reik et al.,Nature, 405, 408-409 (May 25, 2000).
Saitoh et al.,EMBO J., 19 (10), 2315-2322 (2000).
Szabo et al.,Curr. Biol., 10 (10), 607-610 (May 2000).
Thorvaldsen et al.,Science, 288, 2145-2146 (Jun. 23, 2000).
Vostrov et al.,J. Biol. Chem., 277 (2), 1619-1627 (Jan. 11, 2002).
Wolffe,Curr. Biol., 10 (11), R463-R465 (2000).
Wylie et al.,Genome Res., 10 (11), 1711-1718 (2000).
Yang et al.,J. Neurochem., 73 (6), 2286-2298 (Dec. 1999).
Zijlstra et al.,Nature, 342, 435-438 (Nov. 1989).
Lobanenkov Victor V.
Loukinov Dmitri I.
Morse, III Herbert C.
Gussow Anne M.
Helms Larry R.
Leydig , Voit & Mayer, Ltd.
The United States of America as represented by the Department of
LandOfFree
Brother of the regulator of imprinted sites (BORIS) does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Brother of the regulator of imprinted sites (BORIS), we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Brother of the regulator of imprinted sites (BORIS) will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3951509